|
retina |
8 |
|
diabetic retinopathy |
5 |
|
inflammation |
5 |
|
age-related macular degeneration |
4 |
|
myopia |
4 |
|
neovascularization |
4 |
|
adult |
3 |
|
aged |
3 |
|
antioxidant |
3 |
|
best corrected visual acuity |
3 |
|
blindness |
3 |
|
carotenoid |
3 |
|
cell damage |
3 |
|
cell death |
3 |
|
clinical article |
3 |
|
collagen–alginate composite hydrogel |
3 |
|
controlled study |
3 |
|
conventional glycemic control |
3 |
|
diabetes |
3 |
|
dietary supplement |
3 |
|
doxycycline |
3 |
|
drusen |
3 |
|
electroretinography |
3 |
|
encapsulated cell therapy |
3 |
|
eye |
3 |
|
eye disease |
3 |
|
ganciclovir |
3 |
|
hek cells |
3 |
|
homeostasis |
3 |
|
insulin dependent diabetes mellitus |
3 |
|
intense glycemic control |
3 |
|
intravitreal |
3 |
|
light-triggered drug release |
3 |
|
machine learning |
3 |
|
nanotechnology |
3 |
|
natural product |
3 |
|
neuroprotection |
3 |
|
non insulin dependent diabetes mellitus |
3 |
|
ocular drug delivery |
3 |
|
ocular stress |
3 |
|
ophthalmic specialty clinics |
3 |
|
oxidative stress |
3 |
|
public health care system |
3 |
|
regulated cell death |
3 |
|
retinoblastoma |
3 |
|
self-assembly |
3 |
|
sustained drug delivery |
3 |
|
traditional chinese medicine (tcm) |
3 |
|
triage |
3 |
|
trigonal small molecules |
3 |
|
vessel |
3 |
|
vision |
3 |
|
applications |
2 |
|
cataract surgery |
2 |
|
clinic |
2 |
|
cmv |
2 |
|
crystallization |
2 |
|
cytomegalovirus retinitis |
2 |
|
diabetic macular edema |
2 |
|
emulsification |
2 |
|
flavonoid |
2 |
|
healthcare |
2 |
|
herbal extracts |
2 |
|
immunoglobulin g4 related disease |
2 |
|
immunoglobulin g4 related ophthalmic disease |
2 |
|
intraocular |
2 |
|
malignancies |
2 |
|
ocular adnexal lymphoma |
2 |
|
oil |
2 |
|
ophthalmologist |
2 |
|
ophthalmology |
2 |
|
pediatric |
2 |
|
retinal detachment |
2 |
|
silicone oil |
2 |
|
standardized incidence ratios |
2 |
|
tamponade |
2 |
|
vitreoretinal surgery |
2 |
|
age related macular degeneration |
1 |
|
allele |
1 |
|
angiogenesis |
1 |
|
anti-vegf |
1 |
|
anti-vegf non-responder |
1 |
|
anticardiolipin antibody |
1 |
|
arms2 gene |
1 |
|
artificial intelligence |
1 |
|
axenfeld-rieger syndrome |
1 |
|
benign prostatic hypertrophy |
1 |
|
cancer |
1 |
|
cfh gene |
1 |
|
child |
1 |
|
choroidal neovascular membrane |
1 |
|
choroidal neovascularization |
1 |
|
clinical outcome |
1 |
|
cme |
1 |
|
coats disease |
1 |
|
confidence |
1 |
|
corneal neovascularization |
1 |
|
corticosteroids |
1 |
|
curriculum |
1 |
|
deep learning |
1 |
|
deferoxamine |
1 |
|
dexamethasone implant |
1 |
|
diabetes mellitus |
1 |
|
drug therapy |
1 |
|
drugs |
1 |
|
endoscope |
1 |
|
endoscopic vitrectomy |
1 |
|
enucleation |
1 |
|
exudative retinal detachment |
1 |
|
eye surgery |
1 |
|
flomax |
1 |
|
genetics |
1 |
|
hallermann-streiff syndrome |
1 |
|
heavy silicone oil |
1 |
|
heritability |
1 |
|
human |
1 |
|
intraoperative floppy iris syndrome |
1 |
|
intravitreal bevacizumab |
1 |
|
inverted inner limiting membrane peel |
1 |
|
large macular holes |
1 |
|
leukocoria |
1 |
|
mek 1 and 2 |
1 |
|
meta-analysis |
1 |
|
morning glory syndrome |
1 |
|
neovascular age-related macular degeneration |
1 |
|
optic nerve coloboma |
1 |
|
optical coherence tomography |
1 |
|
ozurdex |
1 |
|
pars plana vitrectomy |
1 |
|
pediatric retina |
1 |
|
pitx2 |
1 |
|
placental growth factor |
1 |
|
poor responder |
1 |
|
posturing |
1 |
|
proliferative vitreoretinopathy |
1 |
|
ranibizumab and amd |
1 |
|
rb1 mutation |
1 |
|
refractory macular holes |
1 |
|
retina disease |
1 |
|
retrobulbar cyst |
1 |
|
scleral buckling |
1 |
|
tamsulosin |
1 |
|
telangiectasia |
1 |
|
tnmh classification |
1 |
|
treatment other |
1 |
|
vascular endothelial growth factor |
1 |
|
vitrectomy |
1 |
